Orion Oyj Class B represents the publicly traded Class B shares of Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company devel... Orion Oyj Class B represents the publicly traded Class B shares of Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company develops, manufactures, and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients, with a primary focus on treatments for central nervous system disorders, oncology, respiratory diseases, prostate cancer, Parkinson's disease, asthma, chronic obstructive pulmonary disease, and inflammatory pain. Notable products include Nubeqa for prostate cancer, Stalevo and Comtess for Parkinson's, Easyhaler inhalers for respiratory conditions, and veterinary drugs like Domosedan and Antisedan. Orion Oyj serves specialists, general practitioners, veterinarians, pharmacies, hospitals, and laboratories, with its core market in Finland and additional presence across Europe, North America, and other regions. Employing around 3,989 people, it operates in the pharmaceuticals and biotech sector, contributing to healthcare innovation through proprietary developments, contract manufacturing, and strategic collaborations for antibody therapeutics.
Energy Management data not yet covered for Orion Oyj
We have not yet reviewed Orion Oyj's disclosures for Energy Management data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.
Account Restricted
Your account has been restricted and you no longer have access to paid features.
Contact our support team
or
upgrade your plan
to unblock your account.